Minimal Residual Disease (MRD) Analysis for B-ALL
Are you concerned about B-cell Acute Lymphoblastic Leukemia (B-ALL)? At DNA Labs UAE, we offer the Minimal Residual Disease (MRD) analysis, a diagnostic test that can detect and monitor the presence of very small amounts of cancer cells in the bone marrow or blood of patients with B-ALL.
Test Details
The MRD analysis for B-ALL is a highly sensitive test that can detect residual cancer cells at levels as low as one cancer cell in 10,000 to one million normal cells. It is performed after initial treatment, such as chemotherapy, to determine the effectiveness of the treatment and predict the risk of relapse.
Test Components
- CD10
- CD13
- CD15
- CD19
- CD20
- CD33
- CD34
- CD38
- CD45
- CD58
- CD73
- CD86
- CD123
- CD200
- SYTO-16
Test Price
The cost of the MRD analysis for B-ALL is 2430.0 AED.
Sample Condition
For the test, a 3 mL (1 mL min.) bone marrow aspirate is required in a Green Top (Sodium Heparin) tube. It is essential to ship the sample immediately at 18-22°C and not freeze it. Additionally, it is mandatory to provide the date and time of sampling, previous immunophenotype report, and clinical history.
Report Delivery
The sample is collected daily by 9 am, and the report is delivered on the next working day.
Method
The MRD analysis for B-ALL is conducted using Flow Cytometry.
Test Type
The MRD analysis for B-ALL is specifically designed for patients with Leukemia.
Doctor
The test is performed under the supervision of an Oncologist.
Test Department
The MRD analysis for B-ALL is conducted in our Flow Cytometry department.
Pre Test Information
Prior to the test, it is mandatory to provide the date and time of sampling, previous immunophenotype report, and clinical history.
About MRD Analysis for B-ALL
Minimal Residual Disease (MRD) analysis for B-ALL is a diagnostic test used to detect and monitor the presence of very small amounts of cancer cells in the bone marrow or blood of patients with B-ALL. This test is typically performed after initial treatment, such as chemotherapy, to assess the effectiveness of the treatment and predict the risk of relapse.
The MRD analysis for B-ALL is highly sensitive and can detect residual cancer cells at extremely low levels. It involves the use of flow cytometry or polymerase chain reaction (PCR) techniques to identify and quantify specific markers or genetic abnormalities associated with B-ALL cells. These markers or abnormalities are unique to the cancer cells and not present in normal cells.
During the test, a sample of bone marrow or blood is collected from the patient and processed in the laboratory. The cancer cells are then isolated and analyzed using the chosen technique. The results are reported as a percentage or absolute number of cancer cells present in the sample.
Importance of MRD Analysis for B-ALL
MRD analysis is a crucial tool in the management of B-ALL. It helps clinicians make informed decisions about further treatment options based on the level of MRD detected. If MRD is found at high levels after initial treatment, additional therapies may be required to eliminate the remaining cancer cells and reduce the risk of relapse. On the other hand, if MRD is undetectable or at very low levels, it indicates a favorable response to treatment and a lower risk of relapse.
Overall, MRD analysis for B-ALL plays a crucial role in assessing treatment response, guiding treatment decisions, and monitoring disease progression in patients with B-ALL.
| Test Name | MINIMAL RESIDUAL DISEASE MRD ANALYSIS FOR B- ALL Test |
|---|---|
| Components | *CD10*CD13*CD15*CD19*CD20*CD33 *CD34*CD38*CD45*CD58*CD73*CD86 *CD123*CD200*SYTO-16 |
| Price | 2430.0 AED |
| Sample Condition | 3 mL (1 mL min.) First pull Bone Marrow aspiratein 1 Green Top (Sodium Heparin) tube. Ship immediately at 18-22?\u00f8C. DO NOT FREEZE. It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history. |
| Report Delivery | Sample Daily by 9 am; Report Next Working day |
| Method | Flow Cytometry |
| Test type | Leukemia |
| Doctor | Oncologist |
| Test Department: | FLOW CYTOMETRY |
| Pre Test Information | It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history. |
| Test Details | Minimal Residual Disease (MRD) analysis for B-ALL (B-cell Acute Lymphoblastic Leukemia) is a diagnostic test used to detect and monitor the presence of very small amounts of cancer cells in the bone marrow or blood of patients with B-ALL. MRD analysis is performed after initial treatment, such as chemotherapy, to determine the effectiveness of the treatment and to predict the risk of relapse. It is a highly sensitive test that can detect residual cancer cells at levels as low as one cancer cell in 10,000 to one million normal cells. The MRD analysis for B-ALL typically involves the use of flow cytometry or polymerase chain reaction (PCR) techniques to identify and quantify specific markers or genetic abnormalities associated with B-ALL cells. These markers or abnormalities are unique to the cancer cells and not present in normal cells. During the test, a sample of bone marrow or blood is collected from the patient and processed in the laboratory. The cancer cells are then isolated and analyzed using the chosen technique. The results are reported as a percentage or absolute number of cancer cells present in the sample. MRD analysis is an important tool in the management of B-ALL as it helps clinicians make informed decisions about further treatment options. If MRD is detected at high levels after initial treatment, additional therapies may be required to eliminate the remaining cancer cells and reduce the risk of relapse. On the other hand, if MRD is undetectable or at very low levels, it indicates a favorable response to treatment and a lower risk of relapse. Overall, MRD analysis for B-ALL plays a crucial role in assessing treatment response, guiding treatment decisions, and monitoring disease progression in patients with B-ALL. |
